Onconova Therapeutics Inc. (ONTX)
$12.80
$4.87
(61.41%)
As on 03-Sep-2026 14:22EDT
Market cap
$21 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-4 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
21,003,400
10 Years Aggregate
CFO
$-248.83 Mln
EBITDA
$-270.69 Mln
Net Profit
$-251.73 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Onconova Therapeutics (ONTX)
| -- | -- | -- | -- | 152.5 | 19.4 | -32.7 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Onconova Therapeutics (ONTX)
| 16.2 | -74.5 | -63.5 | 21.6 | -81.8 | -90.5 | -33.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Onconova Therapeutics (ONTX)
Under normal circumstances, the fund will invest at least 80% of the value of its net assets, plus any borrowings for investment purposes, in financial instruments (for example, swaps and futures) that, in the aggregate, provide leveraged exposure to... the Underlying Security equal to approximately two times its daily performance. It is non-diversified. Read more
-
CEO, President & Director
Dr. Steven M. Fruchtman M.D.
-
CEO, President & Director
Dr. Steven M. Fruchtman M.D.
-
Headquarters
Newtown, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Onconova Therapeutics (ONTX)
What is the current share price of Onconova Therapeutics Inc (ONTX) Today?
The share price of Onconova Therapeutics Inc (ONTX) is $12.80 (NASDAQ) as of 03-Sep-2026 14:22 EDT. Onconova Therapeutics Inc (ONTX) has given a return of 152.51% in the last 3 years.
What is the current PB & PE ratio of Onconova Therapeutics Inc (ONTX)?
Since, TTM earnings of Onconova Therapeutics Inc (ONTX) is negative, P/E ratio is not available.
The P/B ratio of Onconova Therapeutics Inc (ONTX) is 1.86 times as on 02-May-2024, a 76 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Onconova Therapeutics Inc (ONTX)?
The 52-week high and low of Onconova Therapeutics Inc (ONTX) are Rs 12.93 and Rs 12.78 as of 04-Sep-2026.
What is the market cap of Onconova Therapeutics Inc (ONTX)?
Onconova Therapeutics Inc (ONTX) has a market capitalisation of $ 21 Mln as on 02-May-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Onconova Therapeutics Inc (ONTX)?
Before investing in Onconova Therapeutics Inc (ONTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.